Reverberi Gian Piero 4
4 · Vanda Pharmaceuticals Inc. · Filed Jan 4, 2018
Insider Transaction Report
Form 4
Reverberi Gian Piero
SVP, General Manager Europe
Transactions
- Exercise/Conversion
Common Stock
2018-01-02+12,500→ 87,500 total - Exercise/Conversion
Common Stock
2018-01-02+7,500→ 110,000 total - Exercise/Conversion
Restricted Stock Unit
2018-01-02−12,500→ 25,000 total→ Common Stock (12,500 underlying) - Exercise/Conversion
Restricted Stock Unit
2018-01-02−7,500→ 15,000 total→ Common Stock (7,500 underlying)
Footnotes (6)
- [F1]Each Restricted Stock Unit ("RSU") was previously reported on Table II on a Form 4 filed with the Securities and Exchange Commission ("SEC") on September 8, 2015.
- [F2]Each RSU represents a contingent right to receive a share of the Issuer's Common Stock.
- [F3]Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II.
- [F4]Each RSU was previously reported on Table II on a Form 4 filed with the SEC on February 17, 2016.
- [F5]The RSUs vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F6]Not Applicable.